Hugel saw the highest growth of 0.32% in patent filings and no patents were granted in April in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 0.32% and no change in grants. GlobalData’s DataBook provides a comprehensive analysis of Hugel’s patent filings and grants. Buy the databook here.
Hugel has been focused on protecting inventions in European Patent Office(EPO) with one publication in Q2 2024
The European Patent Office(EPO) Patent Office dominates the patent filings with nearly 100% of filings. The European Patent Office(EPO) patent Office are among the top ten patent offices where Hugel is filings its patents..
AbbVie and Revance Therapeutics could be the strongest competitors for Hugel
In terms of grant share, Hugel stands in seventh position among its competitors. AbbVie and Revance Therapeutics secured the top positions according to recent patent publication data.
Patents related to climate change lead Hugel's portfolio
Hugel has the highest number of patents in climate change. For climate change, nearly 100% of patents were filed and no patents were granted in Q2 2024.
For comprehensive analysis of Hugel's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.